(Reuters) - Eli Lilly and Co said a late-stage trial testing its lung cancer drug Alimta failed to meet the main study goal of improving overall survival of patients. Patients on the trial, named Pointbreak, were given either a combination of Alimta and Roche Holding AG's cancer drug Avastin along with chemotherapy, or just Avastin along with chemotherapy drugs. (Reporting by Esha Dey in Bangalore) via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment